Drug Profile
Magnesium citrate - RMJ Holdings
Alternative Names: RMJH-111BLatest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator RMJ Holdings
- Class Antihypertensives; Citrates; Laxatives; Magnesium compounds; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Essential hypertension
Most Recent Events
- 15 Feb 2022 Phase-II clinical trials in Essential hypertension in USA (PO) (RMJ Holdings pipeline, February 2022)
- 28 Sep 2021 Interim adverse events, efficacy and pharmacokinetics data from the phase I/II trial in Essential hypertension released by RMJ Holdings
- 04 Dec 2019 Chemical structure information added